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ABSTRACT
Diabetes mellitus (DM) has wider neurological complications. They include upper gastrointestinal (GI) symptoms, impaired motility, 
impaired gastric emptying (GE) and diabetic gastroparesis (DG), which are usually found. The patient was a 64-year-old man with 
type 2 diabetes (T2D) for 22-years. The patient weighed 74 kg with body mass index (BMI) 23.6 kg/m2, hemoglobin A1C (HbA1c) 
9.2%, ankle brachial index (ABI) 1.19/1.23, AST 25 U/L(7-38), ALT 23 U/L(4-44), GGT 48 U/L(<86), Chest X-P normal, and 
electrocardiogram (ECG) negative. When the patient was treated with low carbohydrate diet (LCD), a significant reduction in body 
weight and HbA1c was observed. Abdominal computerized tomography (CT) revealed multiple gall stone, dilated common bile duct 
and impaired GE, indicating DG. For endoscopic examination, much food residue was found in the stomach due to DG after 13 
hours fasting. Treatment for DG was initiated by mosapride citrate hydrate. During clinical progress, occasional liver dysfunction 
was observed twice associated with elevation of  AST 196 U/L, GGT 373 U/L and without symptoms, indicating cholestasis-type 
dysfunction. Some possible triggers may be involved in these episodes, such as gall stone, enlarged volume of  stomach due to DG, 
overeating, overdrinking, and other factors. This impressive report will hopefully become a reference for developing diabetic practice 
and research.
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INTRODUCTION
Diabetes mellitus (DM) has been recently a widespread dis-ease. According to the last data of  International Diabetes 
Federation (IDF), 463 million population has DM with increasing 
prevalence.1 For adequate treatments, several standard guidelines 
of  diabetic therapy have been found, in which American Diabe-
tes Association (ADA) presented recent concept and therapeutic 
management in January 2021.2 DM has given public health burden 
from social and economic aspects. Furthermore, it also brings mac-
roangiopathy and microangiopathy for diabetic patients. Among 
them, neurological complications include upper gastrointestinal 
(GI) symptoms and decreased motility because of  impairment of  
adequate control of  digestive system.3 In recent years, there have 
been various discussion concerning the complications of  diabetes.4 
 From historical point of  view, the usual diet therapy was 
formerly calorie restriction (CR), where fat food was mainly limited 
for reducing total calorie. After a variety of  nutritional practice and 
research for decades, low carbohydrate diet (LCD) was introduced 
for medical and healthcare fields. It was Drs Atkins and Bernstein 
who had shown the effect for diabetes and developed the actual 
methods.5 In the light of  evidence-based medicine, clinical effect 
of  LCD was revealed by some large studies.6 The effective period 
for LCD has been more longer years7 and LCD has become re-
cently rather prevalent in North American and European coun-
tries. 
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 On the other hand, authors and co-researchers have initi-
ated LCD in Japan and developed LCD treatment method so far.8 
We have established Japan LCD Promotion Association (JLCD-
PA), and continued a variety of  opportunities for original papers, 
books, medical societies, seminars and workshops.9 Further, vari-
ous research related to LCD and CR have been reported, including 
meal tolerance test (MTT), insulinogenic index (IGI), continuous 
glucose monitoring (CGM), daily profile of  blood glucose and 
Morbus (M) value.10,11 Recently, we have shown clinical application 
of  Xultophy for type 2 diabetes (T2D) with some medical prob-
lems.12,13 
  Our diabetic team has continued to treat many diabetic 
patients for years.14 Among them, we have reported impressive dia-
betic cases with various complications. We experienced a case in 
which a T2D male patient showed remarkable efficacy for LCD. 
Furthermore, the case had some diabetic complications in the axis 
of  digestive system, including diabetic gastroparesis (DG), occa-
sional liver dysfunction suspected of  probably related with DG. 
This case seems to be clinically impressive, and then general over-




The patient is a 64-year-old man, who had no remarkable illness 
when he was young. His work has been a Buddhist priest and al-
ways busy for long. He was diagnosed with T2D at the age of  
42 and was subsequently treated with oral hypoglycemic agents 
(OHAs). He developed low back pain (LBP) seven years ago and 
was diagnosed with spinal stenosis. Then he received surgical treat-
ment, followed by improvement. Recently, his diabetic control has 
been unstable, and then he was transferred to our diabetic depart-
ment of  the clinic. 
Physical Examination
Consciousness is alert, and speech is normal and ordinary. Vitals 
showed pulse rate 60/min, and blood pressure 132/78 mmHg. His 
physique showed 177 cm in height, 74 kg in weight, 23.6 kg/m2 in 
body mass index (BMI) with ideal body weight (IBW) as 68.9 kg. 
Physicals showed that lung vesicular, heart no significant murmurs, 
abdomen soft and flat, no tenderness, bowel sound audible. Ab-
dominal circumference is 87 cm, and thigh circumference was 43 
cm at 10 cm position from upper border of  patella. Neurological 
findings showed unremarkable.
Examination Results
The results of  biochemical data at first visit were shown in Ta-
ble 1. It showed normal liver function tests and abnormal data 
were not observed. Other examinations were as follows: Chest 
X-P was negative, and electrocardiogram (ECG) was within 
normal limits. The examination of  pulse wave velocity (PWV) 
showed that ankle brachial index (ABI) 1.19/1.23, brachial-ankle 
PWV(baPWV)2453/2669. Echography of  cervical artery revealed 
that maximum data of  intima media thickness (IMT) 0.8/0.8 mm, 
plaque score (PS) 4.5 indicating slight arteriosclerosis (1.1<PS<5.0). 
Clinical Progress
From mentioned above, current medical problems so far are sum-
marized in the following: #1 T2DM, #2 hypertension, #3 arterio-
sclerosis of  carotid artery. For basic treatment of  diabetes, he was 
advised to start LCD. He was provided some medication for #1-3, 
which included sitagliptin phosphate hydrate (Januvia®) 50 mg 1 
Tab, Voglibose (Basen®) 0.3 mg 3 Tab, diltiazem hydrochloride Re-
tard-capsule (Herbesser-R®) 100 mg 1 Tab and aspirin (Biaspyrin®) 
100 mg 1 Tab. 
 By continuing LCD for several months, his hemoglobin 
A1C (HbA1c) values and body weight were decreased. The clini-
cal course is described in Figure 1. For 4-5 months duration of  
LCD, the HbA1c was normalized around 5.6-5.7%, and his clini-
cal progress was stable. Actually, LCD has three levels, which are 
super-LCD, standard-LCD and petite-LCD. They contain the ratio 
of  carbohydrate in calorie as 12%, 26% and 40%, respectively.15 He 
continued super-LCD for 3-months, standard-LCD for 3 months, 
and petite-LCD after that.
 When the patient visited our clinic, we have checked 
echograph and abdominal computerized tomography (CT) scan 
for evaluating the abdominal organs in August, 2018. Abdominal 
CT scan showed the findings of  multiple gall stone, dilation of  
the common bile duct and much amount of  food residue in the 
stomach (Figures 2A and 2B). This finding means impaired gas-
tric emptying and/or delayed gastric emptying (GE). The case is 
diabetic, then it is called as DG. Then, some questions concern-
ing the complaints of  digestive system were asked to the patient. 
The reply included some symptoms of  functional dyspepsia (FD) 
persisting, such as heart burn, abdominal fullness and constipa-
tion. After that, upper gastrointestinal endoscopy was performed 
in September, 2018. The result showed the presence of  extremely 
delayed gastric emptying (Figure 3). Before the exam, the case was 
Table 1. Biochemical Data
CBC GGT 48 U/L (<86) 
Hb 14.1 g/dL ALP 196 U/L (80-260) 
RBC 442 x 106 /μL LDH 179 U/L (124-222)
WBC 7100 /μL T-Bil 0.6 mg/dL (0-1.0)
Plt 26.9x104 /μL CK 124 U/L (41-153) 
BUN 20 mg/dL Amylase 50 U/L (35-125) 
Biochemical CRP 0.2 mg/dL (0-0.6)
Cr 0.9 mg/dL HBs Ag negative
Uric acid 6.8 mg/dL Diabetes-related
TG 144 mg/dL HbA1c 9.2% 
HDL-C 50 mg/dL Glucose 278 mg/dL 
LDL-C 83 mg/dL Urinalysis 
TP 6.6 g/dL Protein (-) 
Alb 3.9 g/dL Sugar (+) 
AST 25 U/L (7-38) Urobilinogen (-) 
ALT 23 U/L (4-44) pH 6
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ordered to keep fasting at least 13-hours from the previous night. 
He had spent usual life, and he did not have any episode of  over-
eating or drinking much related to this. Consequently, the case has 
other medical problems summarized as follows: #4 gall stone, #5 
FD, #6 DG. For the treatment of  #4 and #5, mosapride citrate 
hydrate (Gasmotin®) 5 mg 3 Tab, and sennoside A and B calcium 
(Sennoside®) 12 mg, 2 Tab before sleep a day were started. The ef-
fect of  the both was observed with relieve of  symptoms.
 During his clinical course, liver function was exacerbated 
twice, in March 2019 and in May 2020 (Figure 1). In the first time, 
it rose to AST 196 U/L, ALT 107 U/L, GGT 373 U/L, ALP 396 
U/L, LDH 256. A similar episode was found in the second time, 
with similar changes in liver function tests, which seemed to be 
the medical problem of  #7 occasional cholestasis-type liver dys-
function. In each episode, he did not have the episode of  drinking 
much. He continued a usual life with no particular exacerbated gas-
trointestinal symptoms such as fatigue, abdominal pain, fullness, 
nausea, vomiting, constipation, abnormal bowel movements and 
jaundice. At that period, liver function-related tests in detail were 
conducted. The results showed that T-Bil 0.3 mg/dL, alpha-feto-
protein (AFP) <2.0 ng/mL (<20), Alb 58.2% (60.2-71.4), α1-Glb 
2.2%, α2-Glb 8.7%, β-Glb 9.3%, γ-Glb 21.6% (10.5-20.3), A/G 
ratio 1.3 (1.5-2.5) as proteinogram. These results also suggested 
the existence of  # 8 chronic liver disease (CLD). No particular 
liver dysfunction has been observed since June 2020.
 Another diabetic problem was found concerning retinop-
athy. He was pointed out to have retinopathy at the age of  56-years 
old. The diagnosis was proliferative retinopathy and he received 
Figure 3. Endoscopic Findings: Much Food Residue is Found in the Stomach 
Due to Gastroparesis
Figure 1. Clinical Progress Reduction of HbA1c and Weight and Occasional Liver Dysfunction are Found
Figure 2. Abdominal CT 
A. Transvers view: galls stone and 
gastroparesis are present
B. Coronal view: dilated common bile 
duct are found
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laser treatment in the University Hospital. In February, 2019, he 
complained of  blurred vision, then he was referred to the oph-
thalmology department of  the university hospital. The important 
points of  the diagnosis are summarized in the following. Both eyes 
have diabetic proliferative retinopathy. Previously, cataract surgery 
was performed on the both eyes and intraocular lens were inserted. 
Vitrectomy is performed on the right eye. Currently, the situation 
of  retinopathy has been stable. The intraocular pressure was 18-20 
mmHg for both eyes, and the visual acuity was 0.4 on the right 
and 1.5 on the left in the work of  correction. Since the atrophy 
of  macula is observed in the right eye, it is considered difficult to 
improve visual acuity function in the future. Consequently, he has 
suffered from # 9 proliferative retinopathy for long.
DISCUSSION AND CONCLUSION
This report presents an interesting case. The case is a 64-year-old 
man with T2DM who has a 22-year history of  diabetes. He was re-
ferred to our clinic because of  unstable control. HbA1c and body 
weight were reduced by LCD for a few months, associated with 
remarkable clinical effects. DG, gallstones and common bile duct 
dilation were found in abdominal CT scan. Upper gastrointestinal 
endoscopy examination showed much food residues in the stom-
ach even after fasting for 13 hours. Furthermore, two episodes 
of  occasional liver dysfunction were observed during the clinical 
course. Possible causes are involved in DG, gallstones, common 
bile duct dilation, constipation, overeating and overdrinking. As 
regards to the discussion, 1) LCD, 2) DG, and 3) liver dysfunction 
would be described in this order.
 Firstly, LCD was applied to this case, which showed clini-
cally significant efficacy. HbA1c decreased from 9.2 to 5.6%, and 
body weight decreased from 74 kg to 67 kg for 6-months. The re-
sults seem to be typical case for the clinical efficacy of  LCDs. As to 
another data, TG values were TG 144 mg/dL, 62 mg/dL, 43 mg/
dL, 51 mg/dL, in 0, 3, 6, 9-months from LCD start, respectively. 
Remarkable reduction of  TG is common clinical effects of  LCD 
therapy.7 Authors and colleagues have continued LCD treatment 
for more than 2700 cases with diabetes, obesity and metabolic syn-
drome.16 The results showed that weight reduction was 6.6% in 
average, and 2.6-9.8% in the quartiles of  25-75% associated with 
mean weight reduction as 4.3 kg.
 As regards to LCD, authors have managed to recom-
mend three kinds of  LCD in order to make everyone understand 
and practice easily. They are petite-LCD, standard-LCD and super-
LCD, associated with including carbohydrate ratio for 40%, 26%, 
and 12%, respectively.15 These three types have been actually use-
ful to continue LCD therapy for medical care and healthcare. In 
current case, he has continued super-LCD at first for 3-months, 
successively standard-LCD for 3-months, accompanied by petite-
LCD after that. This trial seems to be satisfactory associated with 
maintaining proper body weight. 
 Secondly, diabetic gastroparesis (DG) has been the impor-
tant medical issue. Diabetic neuropathy has broader concept with 
signs and symptoms, in which various gastrointestinal (GI) symp-
toms are observed. This is so-called diabetic enteropathy (DE).17 
Among DE, autonomic neuropathy show an crucial pathogenetic 
role, associated with reduction of  interstitial cell and expression of  
neuronal NO synthetase.17 Those mechanisms bring to abnormal 
GI motility, leading some symptoms such as nausea, vomiting, dys-
pepsia and constipation. DE has been found in rather larger ratio 
of  diabetic patients. They usually show upper GI symptoms and 
impaired motility.18 Regarding the motility, impaired GE is found 
about 50% of  patients with T1D and T2D who are complaining 
of  FD, diabetic gastroparesis (DG) and so on.19 Since dyspepsia 
and gastroparesis may show similar physio-pathological function 
and clinical signs, the differential diagnosis is not so easy. A recent 
report suggested that FD and DG may show different expressions, 
despite of  the same spectrum of  gastric neuromuscular dysfunc-
tion.20 
 Diabetic gastroparesis has been characterized for its up-
per GI symptoms, including nausea, vomiting, epigastric distress, 
bloating or early satiety, which show without organic obstruction. 
From cumulative proportions of  gastroparesis for >10-years, haz-
ard ratios (HRs) for gastroparesis to controls was 33 in T1D, and 
7.5 in T2D. Further, gastroparesis risk in T1DM was higher than in 
T2D (HR 4.4), and T1D showed association of  gastroparesis and 
heartburn more at baseline (HR 6.6).21 Although gastric emptying 
is often delayed in gastroparesis, overall changed motility does not 
correlate with the symptom severity.22  
 The term dyspepsia includes a set of  symptoms with 
epigastric localization, which can be episodic or persistent, with 
variable intensity and severity. In the clinical setting, it is often dif-
ficult to characterize these symptoms and to distinguish dyspepsia 
from other GI disorders such as gastroesophageal reflux disease 
(GERD).23 The American College of  Gastroenterology (ACG) 
and Canadian Association of  Gastroenterology (CAG) clinical 
guidelines give a useful definition of  dyspepsia as predominant epi-
gastric pain which lasts at least one month and is associated with 
any other upper GI symptom such as epigastric fullness, nausea, 
vomiting or heartburn.24
 Regarding the treatment of  diabetic enteropathy and/or 
DG, three options are present.18 They are i) proper dietary modifi-
cation, ii) restriction of  glucose intake with better glucose control, 
iii) the first-line of  pharmacological therapy such as the use of  pro-
kinetics. For treatment of  GE, there are serotonin type 4 (5-HT4) 
receptor agonists such as mosapride, cisapride that is also effective 
for reduction of  abdominal pain.25 Furthermore, dopamine-2 re-
ceptor antagonists are also present such as metoclopramide that is 
effective for reduction of  early satiety, nausea and vomiting. As a 
5-HT4 receptor agonist, mosapride citrate hydrate (mosapride r) 
has been known to show beneficial effect and to enhance GE.26 
Mosapride combined with a Proton Pump Inhibitor (PPI) signifi-
cantly improved the reflux symptom score compared with that of  
PPI alone.27 
 Thirdly, occasional liver dysfunction twice during the 
clinical course were observed (Figure 1). What kind factors may 
be involved in these episodes? Some possible triggers would be 
gall stone, enlarged volume of  stomach due to DG, overeating, 
overdrinking, and other factors. We had taken detail history of  
daily life from the patient, but he did not notice particular changes 
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in his status. The gall stone was silent for symptoms, showing no 
abdominal pain or discomfort in right upper quadrant. CT find-
ings showed some bile duct enlargement, which may be related the 
presence of  gall stone. Gallstones seemed to be small cholesterol 
stones, and the possibility of  bile duct cancer will be followed and 
checked hereafter. There was a possibility of  the relationship of  
gall stone and occasional liver dysfunction. However, responsible 
causes have not be clarified yet. Consequently, this case will be 
followed-up carefully from several points of  view.
 There are some limitations in this report. The case is lim-
ited one case with DG and occasional liver dysfunction. In detail, 
he seemed to show always delayed gastroparesis and two episodes 
of  liver dysfunction. Its pathophysiological mechanism and situa-
tion would be considered associated with several factors, such as 
medical history, diabetic complication, and interactions in digestive 
system.
 In summary, a patient with T2D was described with 
several medical problems. He showed satisfactory reduction of  
HbA1c and weight by LCD, GI tract problems such as diabetic 
gastroparesis, and occasional liver dysfunction. This impressive 
report will hopefully become a reference for developing diabetic 
practice and research.
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